GB2302021A
(en)
*
|
1996-10-16 |
1997-01-08 |
Lilly Co Eli |
Inhibiting bone loss or resorption
|
US5858753A
(en)
*
|
1996-11-25 |
1999-01-12 |
Icos Corporation |
Lipid kinase
|
US6413773B1
(en)
|
1998-06-01 |
2002-07-02 |
The Regents Of The University Of California |
Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
|
JP2003523166A
(ja)
*
|
1998-09-29 |
2003-08-05 |
ガミダ セル リミテッド |
幹細胞および前駆細胞の増殖と分化を制御する方法
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
CA2359244C
(en)
*
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
WO2001024826A2
(en)
*
|
1999-10-06 |
2001-04-12 |
The Brigham And Women's Hospital, Inc. |
Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
SI2223922T1
(sl)
|
2000-04-25 |
2016-04-29 |
Icos Corporation |
Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
|
AU2002258798A1
(en)
*
|
2001-04-13 |
2002-10-28 |
Children's Hospital Medical Center |
Methods for the treatment of hepatic disorders
|
US7371763B2
(en)
*
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
GB0119865D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
GB0119863D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
US7081475B2
(en)
*
|
2001-09-14 |
2006-07-25 |
Prolx Pharmaceuticals Corp. |
Wortmannin analogs and methods of using same
|
US6703414B2
(en)
*
|
2001-09-14 |
2004-03-09 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Device and method for treating restenosis
|
US20080108672A1
(en)
*
|
2002-01-11 |
2008-05-08 |
Bernd Riedl |
Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
|
IL152904A0
(en)
*
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
EP1465982A4
(de)
*
|
2002-01-25 |
2006-06-07 |
Gamida Cell Ltd |
Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
US7049313B2
(en)
|
2002-02-25 |
2006-05-23 |
Kudos Pharmaceuticals Ltd. |
ATM inhibitors
|
US20050054097A1
(en)
*
|
2002-11-17 |
2005-03-10 |
Tony Peled |
EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
|
US7230139B2
(en)
*
|
2002-12-05 |
2007-06-12 |
Gemin X Biotechnologies |
Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
US20050054103A1
(en)
*
|
2003-03-07 |
2005-03-10 |
Tony Peled |
Expansion of renewable stem cell populations using modulators of PI 3-kinase
|
US20040213757A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Wyeth Holdings Corporation |
Water soluble wortmannin derivatives
|
PT1626714E
(pt)
*
|
2003-05-20 |
2007-08-24 |
Bayer Pharmaceuticals Corp |
Diarilureias para doenças mediadas por pdgfr
|
ES2297490T3
(es)
*
|
2003-07-23 |
2008-05-01 |
Bayer Pharmaceuticals Corporation |
Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
|
US7429660B2
(en)
|
2003-08-13 |
2008-09-30 |
Kudos Pharmaceuticals Limited |
ATM inhibitors
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
WO2005016348A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Method of inhibiting immune responses stimulated by an endogenous factor
|
HUE030950T2
(en)
|
2004-05-13 |
2017-06-28 |
Icos Corp |
Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
|
CA2567883A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
|
JP5371426B2
(ja)
|
2004-07-09 |
2013-12-18 |
プロルックス ファーマシューティカルズ コープ. |
ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
|
WO2006030442A2
(en)
*
|
2004-09-16 |
2006-03-23 |
Gamida-Cell Ltd. |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
US20070238731A1
(en)
|
2004-09-20 |
2007-10-11 |
Kudos Pharmaceuticals Limited |
Dna-Pk Inhibitors
|
TW200626610A
(en)
*
|
2004-10-13 |
2006-08-01 |
Wyeth Corp |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
TW200638938A
(en)
|
2005-02-09 |
2006-11-16 |
Kudos Pharm Ltd |
ATM inhibitors
|
WO2006089106A2
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
AR053358A1
(es)
|
2005-04-15 |
2007-05-02 |
Cancer Rec Tech Ltd |
Inhibidores de adn - pk
|
WO2006117567A2
(en)
*
|
2005-05-05 |
2006-11-09 |
Chroma Therapeutics Ltd |
Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
|
US20090305236A1
(en)
*
|
2005-05-11 |
2009-12-10 |
Genetic Technologies Limited |
Methods of enriching fetal cells
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
ES2378780T3
(es)
*
|
2005-12-30 |
2012-04-17 |
Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona |
Metabolitos de análogos de wortmanina y métodos de uso de los mismos
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
CA3092449A1
(en)
|
2008-11-13 |
2010-05-20 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US20100233733A1
(en)
*
|
2009-02-10 |
2010-09-16 |
Nodality, Inc., A Delaware Corporation |
Multiple mechanisms for modulation of the pi3 kinase pathway
|
EP2411391A1
(de)
|
2009-03-24 |
2012-02-01 |
Gilead Calistoga LLC |
Atropisomere von 2-purinyl-3-tolylchinazolinonderivaten und anwendungsverfahren
|
ES2548253T3
(es)
*
|
2009-04-20 |
2015-10-15 |
Gilead Calistoga Llc |
Métodos para el tratamiento de tumores sólidos
|
MX2012000817A
(es)
|
2009-07-21 |
2012-05-08 |
Gilead Calistoga Llc |
Tratamiento para desordenes del higado con inhibidores pi3k.
|
TR201809040T4
(tr)
*
|
2011-03-21 |
2018-07-23 |
Vivolux Ab |
Solid tümörlerin tedavisi.
|
CA2863795A1
(en)
|
2012-02-13 |
2013-08-22 |
Gamida-Cell Ltd. |
Culturing of mesenchymal stem cells
|
PE20141792A1
(es)
|
2012-03-05 |
2014-12-07 |
Gilead Calistoga Llc |
Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
JP6258332B2
(ja)
|
2012-09-21 |
2018-01-10 |
ヴィヴォルックス アーベー |
固形腫瘍の治療手段及び方法
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
EP3083623A1
(de)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
|
CA2934531C
(en)
|
2013-12-20 |
2020-02-25 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
CN106459005A
(zh)
|
2014-06-13 |
2017-02-22 |
吉利德科学公司 |
磷脂酰肌醇3‑激酶抑制剂
|